Sobi Reports Strong Growth and Strategic Advancements in 2025 Financial Results

Swedish Orphan Biovitrum AB, commonly referred to as Sobi, has recently unveiled its financial report for the fourth quarter and the entire year of 2025. As a prominent global biopharmaceutical company, Sobi's efforts to improve the lives of individuals with rare diseases are consistently reflected in its financial progress.

Fourth Quarter 2025 Highlights

In the fourth quarter of 2025, Sobi witnessed a remarkable revenue increase of 5% compared to the previous year, reaching SEK 7,821 million. When adjusted for constant exchange rates, the growth climbs to an impressive 16%. Notably, the company saw a 25% increase in haematology revenue to SEK 5,143 million. This surge was primarily fueled by the exceptional sales of Altuvoct, which brought in SEK 1,023 million, and Doptelet, generating SEK 1,508 million in revenue. While sales fluctuated slightly with Vonjo, bringing in SEK 327 million, the overall growth in haematology sector was substantial.

Conversely, immunology revenue displayed a more modest increase of 2% at constant exchange rates, totaling SEK 2,337 million. Key contributors to this growth included the sales of Gamifant, which rose significantly to SEK 763 million, and Kineret, which garnered SEK 741 million. However, the revenue from Beyfortus royalties experienced a decline, totaling SEK 849 million, down from SEK 1,207 million.

The strategic portfolio also exhibited robust growth, with a remarkable increase of 37% at constant exchange rates, culminating in SEK 5,059 million. The adjusted EBITA margin reached an impressive 41%, surpassing the previous year's rate of 34%. Overall, EBIT has increased sharply, reflecting a solid operational performance.

Earnings per share (EPS) before dilution rose to SEK 5.39 from SEK 4.07, while after dilution, it stood at SEK 5.34 compared to SEK 4.02 last year. Furthermore, adjusted EPS figures showed a similar positive trend, emphasizing the company’s profitability.

Cash flow from operating activities also demonstrated a healthy increase, amounting to SEK 2,981 million, compared to SEK 1,797 million the previous year, showcasing Sobi's improving operational efficacy.

Full Year 2025 Performance

For the full year of 2025, Sobi reported total revenue growth of 8%, and a 15% rise at constant exchange rates, reaching SEK 28,238 million. In this period, the haematology sector showed a remarkable growth rate of 23% at constant exchange rates, indicating the success of Sobi’s ongoing strategies and product development in this niche.

The adjusted EBITA margin for the year was reported at 40%, compared to 36% previously. However, the company's board has proposed to withhold dividends for the financial year of 2025, focusing instead on reinvestment towards further advancements.

Looking Ahead to 2026

Sobi’s outlook for 2026 is optimistic, forecasting low double-digit percentage revenue growth at constant exchange rates. The anticipated adjusted EBITA margin will likely remain in the mid-30s percentage of revenue, suggesting a focus on sustaining profitability while pursuing growth.

In a related announcement, Sobi has organized a conference call for investors, analysts, and the media on the same date to discuss these results in-depth and answer questions. Detailed presentations and slides will be accessible on the company’s website.

Sobi continues to position itself as a leader in transforming the lives of individuals with rare diseases, supported by a dedicated workforce of approximately 1,900 employees situated across various regions, including Europe, North America, the Middle East, Asia, and Australia. With revenues hitting SEK 28 billion in 2025, the company maintains a pivotal presence in the biopharma industry, reflected by its active listing on Nasdaq Stockholm under the ticker STOSOBI.

For more information about Sobi and its initiatives, interested parties can refer to the company’s official website and social media platforms. As Sobi progresses into the new year, the healthcare community and stakeholders eagerly await the developments this innovative company will continue to deliver.